Multimorbidity prevalence and health outcome prediction: assessing the impact of lookback periods, disease count, and definition criteria in health administrative data at the population-based level.
Administrative Data
Health outcome prediction
Lookback period
Multimorbidity
Prevalence
Journal
BMC medical research methodology
ISSN: 1471-2288
Titre abrégé: BMC Med Res Methodol
Pays: England
ID NLM: 100968545
Informations de publication
Date de publication:
16 May 2024
16 May 2024
Historique:
received:
14
07
2023
accepted:
08
05
2024
medline:
17
5
2024
pubmed:
17
5
2024
entrez:
16
5
2024
Statut:
epublish
Résumé
Health administrative databases play a crucial role in population-level multimorbidity surveillance. Determining the appropriate retrospective or lookback period (LP) for observing prevalent and newly diagnosed diseases in administrative data presents challenge in estimating multimorbidity prevalence and predicting health outcome. The aim of this population-based study was to assess the impact of LP on multimorbidity prevalence and health outcomes prediction across three multimorbidity definitions, three lists of diseases used for multimorbidity assessment, and six health outcomes. We conducted a population-based study including all individuals ages > 65 years on April 1st, 2019, in Québec, Canada. We considered three lists of diseases labeled according to the number of chronic conditions it considered: (1) L60 included 60 chronic conditions from the International Classification of Diseases (ICD); (2) L20 included a core of 20 chronic conditions; and (3) L31 included 31 chronic conditions from the Charlson and Elixhauser indices. For each list, we: (1) measured multimorbidity prevalence for three multimorbidity definitions (at least two [MM2+], three [MM3+] or four (MM4+) chronic conditions); and (2) evaluated capacity (c-statistic) to predict 1-year outcomes (mortality, hospitalisation, polypharmacy, and general practitioner, specialist, or emergency department visits) using LPs ranging from 1 to 20 years. Increase in multimorbidity prevalence decelerated after 5-10 years (e.g., MM2+, L31: LP = 1y: 14%, LP = 10y: 58%, LP = 20y: 69%). Within the 5-10 years LP range, predictive performance was better for L20 than L60 (e.g., LP = 7y, mortality, MM3+: L20 [0.798;95%CI:0.797-0.800] vs. L60 [0.779; 95%CI:0.777-0.781]) and typically better for MM3 + and MM4 + definitions (e.g., LP = 7y, mortality, L60: MM4+ [0.788;95%CI:0.786-0.790] vs. MM2+ [0.768;95%CI:0.766-0.770]). In our databases, ten years of data was required for stable estimation of multimorbidity prevalence. Within that range, the L20 and multimorbidity definitions MM3 + or MM4 + reached maximal predictive performance.
Sections du résumé
BACKGROUND
BACKGROUND
Health administrative databases play a crucial role in population-level multimorbidity surveillance. Determining the appropriate retrospective or lookback period (LP) for observing prevalent and newly diagnosed diseases in administrative data presents challenge in estimating multimorbidity prevalence and predicting health outcome. The aim of this population-based study was to assess the impact of LP on multimorbidity prevalence and health outcomes prediction across three multimorbidity definitions, three lists of diseases used for multimorbidity assessment, and six health outcomes.
METHODS
METHODS
We conducted a population-based study including all individuals ages > 65 years on April 1st, 2019, in Québec, Canada. We considered three lists of diseases labeled according to the number of chronic conditions it considered: (1) L60 included 60 chronic conditions from the International Classification of Diseases (ICD); (2) L20 included a core of 20 chronic conditions; and (3) L31 included 31 chronic conditions from the Charlson and Elixhauser indices. For each list, we: (1) measured multimorbidity prevalence for three multimorbidity definitions (at least two [MM2+], three [MM3+] or four (MM4+) chronic conditions); and (2) evaluated capacity (c-statistic) to predict 1-year outcomes (mortality, hospitalisation, polypharmacy, and general practitioner, specialist, or emergency department visits) using LPs ranging from 1 to 20 years.
RESULTS
RESULTS
Increase in multimorbidity prevalence decelerated after 5-10 years (e.g., MM2+, L31: LP = 1y: 14%, LP = 10y: 58%, LP = 20y: 69%). Within the 5-10 years LP range, predictive performance was better for L20 than L60 (e.g., LP = 7y, mortality, MM3+: L20 [0.798;95%CI:0.797-0.800] vs. L60 [0.779; 95%CI:0.777-0.781]) and typically better for MM3 + and MM4 + definitions (e.g., LP = 7y, mortality, L60: MM4+ [0.788;95%CI:0.786-0.790] vs. MM2+ [0.768;95%CI:0.766-0.770]).
CONCLUSIONS
CONCLUSIONS
In our databases, ten years of data was required for stable estimation of multimorbidity prevalence. Within that range, the L20 and multimorbidity definitions MM3 + or MM4 + reached maximal predictive performance.
Identifiants
pubmed: 38755529
doi: 10.1186/s12874-024-02243-0
pii: 10.1186/s12874-024-02243-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
113Subventions
Organisme : Fonds de recherche du Québec - Santé
ID : Junior 2
Informations de copyright
© 2024. The Author(s).
Références
Marengoni A, Angleman S, Melis R, Mangialasche F, Karp A, Garmen A, et al. Aging with multimorbidity: a systematic review of the literature. Ageing Res Rev sept. 2011;10(4):430–9.
doi: 10.1016/j.arr.2011.03.003
Ryan BL, Allen B, Zwarenstein M, Stewart M, Glazier RH, Fortin M, et al. Multimorbidity and mortality in Ontario, Canada: a population-based retrospective cohort study. J Comorb déc. 2020;10:2235042X20950598.
Ho ISS, Azcoaga-Lorenzo A, Akbari A, Black C, Davies J, Hodgins P, et al. Examining variation in the measurement of multimorbidity in research: a systematic review of 566 studies. Lancet Public Health août. 2021;6(8):e587–97.
doi: 10.1016/S2468-2667(21)00107-9
Johnston MC, Crilly M, Black C, Prescott GJ, Mercer SW. Defining and measuring multimorbidity: a systematic review of systematic reviews. Eur J Public Health févr. 2019;29(1):182–9.
doi: 10.1093/eurpub/cky098
Simard M, Rahme E, Calfat AC, Sirois C. Multimorbidity measures from health administrative data using ICD system codes: a systematic review. Pharmacoepidemiol Drug Saf Janv. 2022;31(1):1–12.
doi: 10.1002/pds.5368
Juul-Larsen HG, Christensen LD, Andersen O, Bandholm T, Kaae S, Petersen J. Development of the chronic condition measurement guide: a new tool to measure chronic conditions in older people based on ICD-10 and ATC-codes. Eur Geriatr Med. 1 juin. 2019;10(3):431–44.
Lambert L, Blais C, Hamel D, Brown K, Rinfret S, Cartier R, et al. Evaluation of care and surveillance of cardiovascular disease: can we trust medico-administrative hospital data? Can J Cardiol avr. 2012;28(2):162–8.
doi: 10.1016/j.cjca.2011.10.005
Nanditha NGA, Dong X, McLinden T, Sereda P, Kopec J, Hogg RS et al. The impact of lookback windows on the prevalence and incidence of chronic diseases among people living with HIV: an exploration in administrative health data in Canada. BMC Med Res Methodol. 6 janv. 2022;22(1):1.
Chen G, Lix L, Tu K, Hemmelgarn BR, Campbell NRC, McAlister FA, et al. Influence of using different databases and « look back » intervals to define comorbidity profiles for patients with newly diagnosed hypertension: implications for Health services Researchers. PLoS ONE. 2016;11(9):e0162074.
doi: 10.1371/journal.pone.0162074
pubmed: 27583532
pmcid: 5008755
Preen DB, Holman CDJ, Spilsbury K, Semmens JB, Brameld KJ. Length of comorbidity lookback period affected regression model performance of administrative health data. J Clin Epidemiol sept. 2006;59(9):940–6.
doi: 10.1016/j.jclinepi.2005.12.013
Simard M, Sirois C, Candas B. Validation of the combined Comorbidity Index of Charlson and Elixhauser to predict 30-Day mortality across ICD-9 and ICD-10. Med Care Mai. 2018;56(5):441–7.
doi: 10.1097/MLR.0000000000000905
Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol Juill. 2011;64(7):749–59.
doi: 10.1016/j.jclinepi.2010.10.004
Blais C, Jean S, Sirois C, Rochette L, Plante C, Larocque I, et al. Quebec Integrated Chronic Disease Surveillance System (QICDSS), an innovative approach. Chronic Dis Inj Can. 2014;34(Electronic):1925–6523.
Gamache P, Hamel D, Blaser C. L’indice de défavorisation matérielle et sociale: en bref: guide méthodologique. Institut national de la santé publique du Québec; 2019. p. 16.
Calderon-Larranaga A, Vetrano DL, Onder G, Gimeno-Feliu LA, Coscollar-Santaliestra C, Carfi A, et al. Assessing and measuring chronic multimorbidity in the older Population: a proposal for its operationalization. J Gerontol Ser A-Biol Sci Med Sci Oct. 2017;72(10):1417–23.
GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the global burden of Disease Study 2019. Lancet. oct 2020;17(10258):1204–22.
GBD 2019 Diseases and Injuries Collaborators. Global Burden of Disease (GBD). [cité 18 janv 2023]. Disponible sur: https://www.healthdata.org/gbd/2019 .
Klabunde CN, Harlan LC, Warren JL. Data sources for measuring comorbidity: a comparison of hospital records and medicare claims for cancer patients. Med Care. 2006;44(10):921–8.
doi: 10.1097/01.mlr.0000223480.52713.b9
pubmed: 17001263
Parks J, Svendsen D, Singer P, Foti ME. Morbidity and mortality in people with Serious Mental illness. National Association of State Mental Health Program Directors (NASMHPD) Medical Directors Council; 2006. p. 87.
Belzile E, Sanche S, McCusker J, Vadeboncoeur A, Ciampi A, Levesque JF. A measure of emergency department use based on Quebec’s administrative data [technical report]. Montréal: St. Mary’s Research Centre; 2011.
Gaulin M, Simard M, Candas B, Lesage A, Sirois C. Combined impacts of multimorbidity and mental disorders on frequent emergency department visits: a retrospective cohort study in Quebec, Canada. CMAJ. 2019;02(26):E724–32.
doi: 10.1503/cmaj.181712
Mbuya-Bienge C, Simard M, Gaulin M, Candas B, Sirois C. Does socio-economic status influence the effect of multimorbidity on the frequent use of ambulatory care services in a universal healthcare system? A population-based cohort study. BMC Health Serv Res 6 mars. 2021;21(1):202.
doi: 10.1186/s12913-021-06194-w
Steyerberg EW, Vickers AJ, Cook NR, Gerds T, Gonen M, Obuchowski N, et al. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology. 2010;21(Electronic):1531–5487.
Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, Glynn RJ. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol. 2001;154(9):854–64.
doi: 10.1093/aje/154.9.854
pubmed: 11682368
Steyerberg EW. Validation in prediction research: the waste by data splitting. J Clin Epidemiol nov. 2018;103:131–3.
doi: 10.1016/j.jclinepi.2018.07.010
Tonelli M, Wiebe N, Fortin M, Guthrie B, Hemmelgarn BR, James MT, et al. Methods for identifying 30 chronic conditions: application to administrative data. BMC Med Inf Decis Mak 17 avr. 2015;15:31.
doi: 10.1186/s12911-015-0155-5
Hvidberg MF, Johnsen SP, Glümer C, Petersen KD, Olesen AV, Ehlers L. Catalog of 199 register-based definitions of chronic conditions. Scand J Public Health Juill. 2016;44(5):462–79.
doi: 10.1177/1403494816641553
Kondalsamy-Chennakesavan S, Johnson S, Nicklin J, Land R, Garrett A, Obermair A. Charlson’s index: a validation study to predict surgical adverse events in gynecologic oncology. Gynecologic Oncol 1 mars. 2011;120:S121.
doi: 10.1016/j.ygyno.2010.12.291